Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Egeberg

Showing results (301-310 of 332) with videos related to

Pageof 34
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|December 4, 2022
Short-term real-world experience with baricitinib treatment in Danish adults with moderate-severe atopic dermatitisIda Vittrup, Jesper Elberling, Lone Skov, et al.
Acta Dermato-Venereologica|March 3, 2025
Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort StudyJohan Sieborg, Julia-Tatjana Maul, Jashin J Wu, et al.
The British Journal of Dermatology|February 2, 2024
Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort studyHans Christian Ring, Jonathan Thorsen, Brian Kirby, et al.
Acta Dermato-Venereologica|March 12, 2024
Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on PsoriasisJulia-Tatjana Maul, Lara V Maul, Johannes A Didaskalu, et al.
Journal of the American Academy of Dermatology|November 11, 2023
Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)Richard B Warren, Lars E French, Andrew Blauvelt, et al.
The British Journal of Dermatology|April 28, 2026
Preterm Birth Is Associated with Reduced Risk of Atopic Dermatitis and a Distinct Allergic Comorbidity Profile in Early ChildhoodIben Frier Ruge, Mia-Louise Nielsen, Anne Sofie Halling, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 3, 2025
Infant palmar hyperlinearity and type 2 inflammatory markers predict atopic dermatitis at 1 year of ageIben Frier Ruge, Anne-Sofie Halling, Maria Rasmussen Rinnov, et al.
Contact Dermatitis|November 22, 2023
Demographics, characteristics and medical treatment among adults with hand eczema in Denmark. A cross-sectional validation and registry-based studyMaria Oberländer Christensen, Yasemin Topal Yüksel, Ida Vittrup, et al.
Life (Basel, Switzerland)|October 26, 2024
Global Comparison of COVID-19 Vaccination Rates among Psoriasis PatientsEdwin Korouri, Charlotte Jeong, Hannah Peterson, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 6, 2023
A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitisIda Vittrup, Niels Steen Krogh, Henrik Hedegaard Pliess Larsen, et al.
Pageof 34

Showing results (301-310 of 332) with videos related to

Sort By:
Pageof 34
Journal of the European Academy of Dermatology and Venereology : JEADV|December 4, 2022
Short-term real-world experience with baricitinib treatment in Danish adults with moderate-severe atopic dermatitisIda Vittrup, Jesper Elberling, Lone Skov, et al.
Acta Dermato-Venereologica|March 3, 2025
Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort StudyJohan Sieborg, Julia-Tatjana Maul, Jashin J Wu, et al.
The British Journal of Dermatology|February 2, 2024
Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort studyHans Christian Ring, Jonathan Thorsen, Brian Kirby, et al.
Acta Dermato-Venereologica|March 12, 2024
Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on PsoriasisJulia-Tatjana Maul, Lara V Maul, Johannes A Didaskalu, et al.
Journal of the American Academy of Dermatology|November 11, 2023
Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)Richard B Warren, Lars E French, Andrew Blauvelt, et al.
The British Journal of Dermatology|April 28, 2026
Preterm Birth Is Associated with Reduced Risk of Atopic Dermatitis and a Distinct Allergic Comorbidity Profile in Early ChildhoodIben Frier Ruge, Mia-Louise Nielsen, Anne Sofie Halling, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 3, 2025
Infant palmar hyperlinearity and type 2 inflammatory markers predict atopic dermatitis at 1 year of ageIben Frier Ruge, Anne-Sofie Halling, Maria Rasmussen Rinnov, et al.
Contact Dermatitis|November 22, 2023
Demographics, characteristics and medical treatment among adults with hand eczema in Denmark. A cross-sectional validation and registry-based studyMaria Oberländer Christensen, Yasemin Topal Yüksel, Ida Vittrup, et al.
Life (Basel, Switzerland)|October 26, 2024
Global Comparison of COVID-19 Vaccination Rates among Psoriasis PatientsEdwin Korouri, Charlotte Jeong, Hannah Peterson, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 6, 2023
A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitisIda Vittrup, Niels Steen Krogh, Henrik Hedegaard Pliess Larsen, et al.
Pageof 34